Is BOLD or BRNS more undervalued in 2026?

CirclFi compares Boundless Bio, Inc. (BOLD) and Barinthus Biotherapeutics plc (BRNS) using 13 institutional-grade valuation models. BOLD has a Quality of Company score of 4.0/10 while BRNS scores 6.0/10.

Which is a better buy — BOLD or BRNS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BOLD and BRNS valuations compare?

BOLD at $1.46 and BRNS at $0.68 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BOLD vs BRNS Valuation Comparison 2026 — Intrinsic Value Analysis

BOLD

Biotechnology

Boundless Bio, Inc.

Quality

4.0

out of 10

Value Trap

SAFE

Price

$1.46

Last close

Models

7/13

Active

BRNS

Biotechnology

Barinthus Biotherapeutics plc

Quality

6.0

out of 10

Value Trap

SAFE

Price

$0.68

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	BOLD Fair Value	BOLD Upside	BRNS Fair Value	BRNS Upside
Bayesian DCF	Intrinsic	$0.76	-48.1%	$0.94	+37.8%
First Chicago	Scenario	$1.05	-25.9%	$0.26	-63.5%
ML-RIV	Intrinsic	$2.77	+89.6%	$1.59	+133.1%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BOLD vs BRNS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BOLD vs BRNS — Which Stock Is More Undervalued?

BRNS scores higher with a 6.0/10 quality rating vs BOLD's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Boundless Bio, Inc. (BOLD) and Barinthus Biotherapeutics plc (BRNS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BOLD currently trades at $1.46 with a QOC of 4.0/10, while BRNS trades at $0.68 with a QOC of 6.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).